- UroToday Home
- Urologic Oncology
Prostate Cancer Abstracts and Beyond
Recent Abstracts
-
One-Year Functional Satisfaction and Quality of Life Outcomes of Patients With a History of Radiotherapy With Artificial Urinary Sphincters.Prostate CancerJune 4, 2026
-
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.Prostate CancerJune 4, 2026
-
Beyond GnRH analogues: The Renaissance of Estrogens in Prostate Cancer Management.Prostate CancerJune 4, 2026
-
Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis.Prostate CancerJune 4, 2026
-
GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer.Prostate CancerJune 4, 2026
-
USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer.Prostate CancerJune 4, 2026
-
Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.Prostate CancerJune 3, 2026
-
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States.Prostate CancerJune 3, 2026
-
One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study.Prostate CancerJune 3, 2026
-
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.Prostate CancerJune 3, 2026
Beyond the Abstracts
-
Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care - Beyond the AbstractProstate CancerJune 3, 2026
-
Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography-positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial - Beyond the AbstractProstate CancerMay 26, 2026
-
Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review - Beyond the AbstractProstate CancerMay 26, 2026
-
Therapeutic Targeting of Prostate-Specific Membrane Antigen Could Limit Its Potential as Benchmark Imaging - Beyond the AbstractProstate CancerMay 20, 2026
-
Phase II Trial of Combination Radiation, Hormone, and Immunotherapy in Grade Group 5 Prostate Cancer - Beyond the AbstractProstate CancerMay 20, 2026
-
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective - Beyond the AbstractProstate CancerMay 8, 2026
-
Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy - Beyond the AbstractProstate CancerMay 8, 2026
-
Inflammation and Insulin Profiles in Men Assigned to Exercise vs. Usual Care for Prostate Cancer: Results from the Active Surveillance Exercise (ASX) Randomized Controlled Trial - Beyond the AbstractProstate CancerMay 5, 2026
-
Pushing the Boundaries of SBRT in Irradiated Territories for Nodal Oligorecurrent Prostate Cancer: Outcomes of the CYGNUS Multicentric Retrospective Study - Beyond the AbstractProstate CancerMay 5, 2026
-
Plasma Extracellular Vesicle Proteomics Nominates Candidate Biomarkers of 177Lu-PSMA-617 Outcomes in Metastatic Prostate Cancer Patients - Beyond the AbstractProstate CancerMay 5, 2026